Fatma Meric Yilmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fatma Meric Yilmaz has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Özcan Erel
Department of Medical Biochemistry, Ankara Bilkent City Hospital, 06800 Ankara, Turkey
5 shared publications - Canan Topcuoglu
Department of Medical Biochemistry, Etlik City Hospital, Ankara, Türkiye
4 shared publications - Salim Neselioglu
Department of Biochemistry , Ankara Bilkent City Hospital , Ankara , Türkiye
4 shared publications - Esra Fırat Oğuz
Ankara Bilkent Şehir Hastanesi
3 shared publications - Fatma Aybala Altay
The Turkish Society of Clinical Microbiology and Infectious Diseases (KLİMİK), Study Group for Diabetic Foot Infections (SGDFI), İstanbul, Türkiye
3 shared publications - Ihsan Ates
Department of Internal Medicine, Ankara Bilkent City Hospital, Ankara 06800, Türkiye
3 shared publications
Latest Publications
- Open Access
- 3 January 2025
- Published by MDPI AG in Preprints.org
The Utilization of The Large Unstained Cell (LUC) Parameter in Lymphoid, Haematopoietic and Related Tissue’s Malignant Neoplasms
Large unstained cells (LUC) is a differential count parameter reported by routine hematology analysis, and LUC percentages (LUC %) reflect active lymphocytes and peroxidase-negative cells. We aimed the evaluate the LUC % parameter in routine practice towards malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic, and related tissue. LUC analysis was performed with Siemens ADVIA® 2120 Hematology System. Data were obtained from Ankara Bilkent City Hospital’s laboratory information system. A statistical difference in the LUC % data in the case of LUC % <4.5 and LUC % ≥4.5 among preliminary diagnoses was observed (p<0.001). According to the Kruskal-Wallis test, a statistical difference was observed between preliminary diagnosis and LUC % values (p<0.001). The One-way ANOVA test with Bonferroni correction was performed for post hoc multiple comparisons of the preliminary diagnosis among LUC%. LUC % was higher in Hodgkin Lymphoma patients than Myeloid leukaemia patients (p=0.002). LUC % was higher in the Lymphoid leukaemia patients than in the patients with Hodgkin lymphoma (p<0.001), Other and unspecified types of non-Hodgkin lymphoma (p<0.001), Multiple myeloma and malignant plasma cell neoplasms (p<0.001). LUC % was higher in patients with leukemia unspecified cell type than Hodgkin lymphoma (p<0.001), Follicular lymphoma (p<0.001), Non-follicular lymphoma (p<0.001), Mature T/NK-cell lymphomas (p<0.001), Other and unspecified types of non-Hodgkin lymphoma (p<0.001), Malignant immunoproliferative diseases (p<0.001), Multiple myeloma and malignant plasma cell neoplasms (p<0.001), Lymphoid leukaemia (p<0.001), Myeloid leukaemia (p<0.001), Other leukaemias of specified cell type patients (p<0.001). Prospective studies may be useful in assessing LUC%.
- 3 January 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Utilization of The Large Unstained Cell (LUC) Parameter in Lymphoid, Haematopoietic and Related Tissue’s Malignant Neoplasms
Large unstained cells (LUC) is a differential count parameter reported by routine hematology analysis, and LUC percentages (LUC %) reflect active lymphocytes and peroxidase-negative cells. We aimed the evaluate the LUC % parameter in routine practice towards malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic, and related tissue. LUC analysis was performed with Siemens ADVIA® 2120 Hematology System. Data were obtained from Ankara Bilkent City Hospital’s laboratory information system. A statistical difference in the LUC % data in the case of LUC % <4.5 and LUC % ≥4.5 among preliminary diagnoses was observed (p<0.001). According to the Kruskal-Wallis test, a statistical difference was observed between preliminary diagnosis and LUC % values (p<0.001). The One-way ANOVA test with Bonferroni correction was performed for post hoc multiple comparisons of the preliminary diagnosis among LUC%. LUC % was higher in Hodgkin Lymphoma patients than Myeloid leukaemia patients (p=0.002). LUC % was higher in the Lymphoid leukaemia patients than in the patients with Hodgkin lymphoma (p<0.001), Other and unspecified types of non-Hodgkin lymphoma (p<0.001), Multiple myeloma and malignant plasma cell neoplasms (p<0.001). LUC % was higher in patients with leukemia unspecified cell type than Hodgkin lymphoma (p<0.001), Follicular lymphoma (p<0.001), Non-follicular lymphoma (p<0.001), Mature T/NK-cell lymphomas (p<0.001), Other and unspecified types of non-Hodgkin lymphoma (p<0.001), Malignant immunoproliferative diseases (p<0.001), Multiple myeloma and malignant plasma cell neoplasms (p<0.001), Lymphoid leukaemia (p<0.001), Myeloid leukaemia (p<0.001), Other leukaemias of specified cell type patients (p<0.001). Prospective studies may be useful in assessing LUC%.
- Open Access
- 1 March 2018
- Published by Taylor & Francis in Alexandria Journal of Medicine
- Vol. 54 (1) , 11-15
IGF-I and IGFBP-3 levels and their correlations with carcinoembryonic antigen in colorectal cancer patients
Background: Colorectal cancer is one of the most frequently seen cancers worldwide. Currently, CEA is the most commonly used tumor marker in colorectal cancer. The changes in IGF/IGFBP equilibrium is also known to cause carcinogenesis. In this study, we aimed to monitor IGF-I/IGFBP-3 levels, the changes in IGF-I/IGFBP-3 ratio and correlations of these peptides with the common tumor marker CEA. Materials and methods: 55 colorectal cancer patients and 35 control group patients were included in this study. Serum CEA, IGF-I and IGFBP-3 levels of all specimens were measured with chemiluminescence method. Results: In colorectal cancer patients, IGF-I levels was found to be increased, IGFBP-3 levels decreased and IGF-I/IGFBP-3 ratio was increased; when compared to control group (p < 0.05). A moderately significant correlation was found between the conventional tumor marker CEA and IGF-I and IGF-BP3 (p = 0.001, r = 0.533 and p = 0.001, r = -0.573 respectively). Conclusions: IGF-I/IGFBP-3 ratio seems to be increased in the colorectal cancer patients. When considered with the moderate correlation levels of these peptides with CEA, this increase in IGF-I/IGF-BP3 ratio may be useful in monitoring carcinogenesis in colorectal cancer patients among with CEA but more detailed and extensive studies in larger study groups needed to be carried out. (C) 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
- 1 March 2018
- Published by Taylor & Francis in Alexandria Journal of Medicine
- Vol. 54 (1) , 11-15
Open AccessIGF-I and IGFBP-3 levels and their correlations with carcinoembryonic antigen in colorectal cancer patients
Background: Colorectal cancer is one of the most frequently seen cancers worldwide. Currently, CEA is the most commonly used tumor marker in colorectal cancer. The changes in IGF/IGFBP equilibrium is also known to cause carcinogenesis. In this study, we aimed to monitor IGF-I/IGFBP-3 levels, the changes in IGF-I/IGFBP-3 ratio and correlations of these peptides with the common tumor marker CEA. Materials and methods: 55 colorectal cancer patients and 35 control group patients were included in this study. Serum CEA, IGF-I and IGFBP-3 levels of all specimens were measured with chemiluminescence method. Results: In colorectal cancer patients, IGF-I levels was found to be increased, IGFBP-3 levels decreased and IGF-I/IGFBP-3 ratio was increased; when compared to control group (p < 0.05). A moderately significant correlation was found between the conventional tumor marker CEA and IGF-I and IGF-BP3 (p = 0.001, r = 0.533 and p = 0.001, r = -0.573 respectively). Conclusions: IGF-I/IGFBP-3 ratio seems to be increased in the colorectal cancer patients. When considered with the moderate correlation levels of these peptides with CEA, this increase in IGF-I/IGF-BP3 ratio may be useful in monitoring carcinogenesis in colorectal cancer patients among with CEA but more detailed and extensive studies in larger study groups needed to be carried out. (C) 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
The impact of levothyroxine sodium treatment on dynamic thiol/disulphide homeostasis in overt hypothyroidism
Objective: Thiols are organic compounds that contain sulphydryl group (-SH) and have important role in preventing oxidative stress especially in cells. The aim of our study is to investigate the relationship between hypothyroidism due to HT and the thiol disulfide homeostasis, the effect of treatment on this homeostasis and to demonstrate the utility of thiol/disulphide homestasis as a marker for assessing the damage to functional group of proteins and the oxidative balance in this group of patients. Design, patients and measurements: Thirty-five patients with a new diagnosis of hypothyroidism due to HT who were not yet under treatment is enrolled in the study. Serum samples were taken prior to the treatment and 6 months after initiation of levothyroxine sodium treatment to compare clinical and laboratory parameters of patients. Thiol/disulfide homeostasis is evaluated by Erel & Neselioglu method. Results: After 6 months of treatment the native thiol and total thiol levels were significantly increased (P=0.001 and P=0.001). The disulphide level, the disulphide/native thiol and the disulphide/total thiol ratios showed a significant decline (P=0.001, P=0.001, P=0.001 respectively). Conclusion: Decrease in the disulfide/thiol ratio after levothyroxine sodium treatment in hypothyroidism may suggests that treatment plays a role in reducing both oxidative stress and free radical mediated damage to the functional groups of proteins. Thus, it may be possible to avoid the complications caused by oxidative stress. As a result disulfide/thiol ratio may contribute to the management of treatment in hypothyroid patients.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
The impact of levothyroxine sodium treatment on dynamic thiol/disulphide homeostasis in overt hypothyroidism
Objective: Thiols are organic compounds that contain sulphydryl group (-SH) and have important role in preventing oxidative stress especially in cells. The aim of our study is to investigate the relationship between hypothyroidism due to HT and the thiol disulfide homeostasis, the effect of treatment on this homeostasis and to demonstrate the utility of thiol/disulphide homestasis as a marker for assessing the damage to functional group of proteins and the oxidative balance in this group of patients. Design, patients and measurements: Thirty-five patients with a new diagnosis of hypothyroidism due to HT who were not yet under treatment is enrolled in the study. Serum samples were taken prior to the treatment and 6 months after initiation of levothyroxine sodium treatment to compare clinical and laboratory parameters of patients. Thiol/disulfide homeostasis is evaluated by Erel & Neselioglu method. Results: After 6 months of treatment the native thiol and total thiol levels were significantly increased (P=0.001 and P=0.001). The disulphide level, the disulphide/native thiol and the disulphide/total thiol ratios showed a significant decline (P=0.001, P=0.001, P=0.001 respectively). Conclusion: Decrease in the disulfide/thiol ratio after levothyroxine sodium treatment in hypothyroidism may suggests that treatment plays a role in reducing both oxidative stress and free radical mediated damage to the functional groups of proteins. Thus, it may be possible to avoid the complications caused by oxidative stress. As a result disulfide/thiol ratio may contribute to the management of treatment in hypothyroid patients.
- 1 May 2017
- Published by Elsevier in Psychiatry Research
- Vol. 251, 212-216
Thiol/disulfide homeostasis in untreated schizophrenia patients
- 1 May 2017
- Published by Elsevier in Psychiatry Research
- Vol. 251, 212-216
Thiol/disulfide homeostasis in untreated schizophrenia patients
- Open Access
- 14 April 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0153693
Impact of Laboratory Test Use Strategies in a Turkish Hospital
Eliminating unnecessary laboratory tests is a good way to reduce costs while maintain patient safety. The aim of this study was to define and process strategies to rationalize laboratory use in Ankara Numune Training and Research Hospital (ANH) and calculate potential savings in costs. A collaborative plan was defined by hospital managers; joint meetings with ANHTA and laboratory professors were set; the joint committee invited relevant staff for input, and a laboratory efficiency committee was created. Literature was reviewed systematically to identify strategies used to improve laboratory efficiency. Strategies that would be applicable in local settings were identified for implementation, processed, and the impact on clinical use and costs assessed for 12 months. Laboratory use in ANH differed enormously among clinics. Major use was identified in internal medicine. The mean number of tests per patient was 15.8. Unnecessary testing for chloride, folic acid, free prostate specific antigen, hepatitis and HIV testing were observed. Test panel use was pinpointed as the main cause of overuse of the laboratory and the Hospital Information System test ordering page was reorganized. A significant decrease (between 12.6–85.0%) was observed for the tests that were taken to an alternative page on the computer screen. The one year study saving was equivalent to 371,183 US dollars. Hospital-based committees including laboratory professionals and clinicians can define hospital based problems and led to a standardized approach to test use that can help clinicians reduce laboratory costs through appropriate use of laboratory tests.
- 14 April 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0153693
Open AccessImpact of Laboratory Test Use Strategies in a Turkish Hospital
Eliminating unnecessary laboratory tests is a good way to reduce costs while maintain patient safety. The aim of this study was to define and process strategies to rationalize laboratory use in Ankara Numune Training and Research Hospital (ANH) and calculate potential savings in costs. A collaborative plan was defined by hospital managers; joint meetings with ANHTA and laboratory professors were set; the joint committee invited relevant staff for input, and a laboratory efficiency committee was created. Literature was reviewed systematically to identify strategies used to improve laboratory efficiency. Strategies that would be applicable in local settings were identified for implementation, processed, and the impact on clinical use and costs assessed for 12 months. Laboratory use in ANH differed enormously among clinics. Major use was identified in internal medicine. The mean number of tests per patient was 15.8. Unnecessary testing for chloride, folic acid, free prostate specific antigen, hepatitis and HIV testing were observed. Test panel use was pinpointed as the main cause of overuse of the laboratory and the Hospital Information System test ordering page was reorganized. A significant decrease (between 12.6–85.0%) was observed for the tests that were taken to an alternative page on the computer screen. The one year study saving was equivalent to 371,183 US dollars. Hospital-based committees including laboratory professionals and clinicians can define hospital based problems and led to a standardized approach to test use that can help clinicians reduce laboratory costs through appropriate use of laboratory tests.
- 4 April 2016
- Published by Taylor & Francis in Endocrine Research
- Vol. 41 (4) , 343-349
Dynamic thiol/disulfide homeostasis in patients with autoimmune subclinical hypothyroidism
Objective: The aim of this study was to investigate dynamic thiol/disulfide homeostasis in autoimmune subclinical hypothyroidism. Methods: Forty-eight patients with a new diagnosis of subclinical hypothyroidism due to Hashimoto thyroiditis who were not yet under medical therapy, and 48 healthy control subjects were enrolled. Thiol/disulfide homeostasis [native thiol–disulfide exchanges] was measured in both groups using the automated method developed by Erel and Neselioglu. An absolute difference of 0.5 between the total thiol and native thiol concentrations revealed the disulfide bond amount. Results: The native thiol level (p = 0.014) and native thiol/total thiol ratio (p = 0.001) were lower in patients with subclinical hypothyroidism than in the control group. Meanwhile, the disulfide level (p = 0.004), disulfide/native thiol ratio (p = 0.001), and disulfide/total thiol (p = 0.001) ratio were higher in patients with subclinical hypothyroidism than in the control group. The antithyroid peroxidase and anti-thyroglobulin levels were positively correlated with the disulfide/native thiol ratio (r = 0.339, p = 0.019; r = 0.243, p = 0.023, respectively) and the disulfide/total thiol ratio (r = 0.133, p = 0.019; r = 0.238, p = 0.026, respectively) and negatively correlated with the native thiol/total thiol ratio (r = −0.292, p = 0.004; r = −0.233, p = 0.022, respectively). Conclusion: We found that thiol/disulfide homeostasis shifted to disulfide formation in patients with subclinical hypothyroidism and that thyroid autoantibodies were positively correlated with thiol oxidation. It is not clear whether abnormal thiol/disulfide homeostasis is a cause or a consequence in Hashimoto thyroiditis. Further studies are required.
- 4 April 2016
- Published by Taylor & Francis in Endocrine Research
- Vol. 41 (4) , 343-349
Dynamic thiol/disulfide homeostasis in patients with autoimmune subclinical hypothyroidism
Objective: The aim of this study was to investigate dynamic thiol/disulfide homeostasis in autoimmune subclinical hypothyroidism. Methods: Forty-eight patients with a new diagnosis of subclinical hypothyroidism due to Hashimoto thyroiditis who were not yet under medical therapy, and 48 healthy control subjects were enrolled. Thiol/disulfide homeostasis [native thiol–disulfide exchanges] was measured in both groups using the automated method developed by Erel and Neselioglu. An absolute difference of 0.5 between the total thiol and native thiol concentrations revealed the disulfide bond amount. Results: The native thiol level (p = 0.014) and native thiol/total thiol ratio (p = 0.001) were lower in patients with subclinical hypothyroidism than in the control group. Meanwhile, the disulfide level (p = 0.004), disulfide/native thiol ratio (p = 0.001), and disulfide/total thiol (p = 0.001) ratio were higher in patients with subclinical hypothyroidism than in the control group. The antithyroid peroxidase and anti-thyroglobulin levels were positively correlated with the disulfide/native thiol ratio (r = 0.339, p = 0.019; r = 0.243, p = 0.023, respectively) and the disulfide/total thiol ratio (r = 0.133, p = 0.019; r = 0.238, p = 0.026, respectively) and negatively correlated with the native thiol/total thiol ratio (r = −0.292, p = 0.004; r = −0.233, p = 0.022, respectively). Conclusion: We found that thiol/disulfide homeostasis shifted to disulfide formation in patients with subclinical hypothyroidism and that thyroid autoantibodies were positively correlated with thiol oxidation. It is not clear whether abnormal thiol/disulfide homeostasis is a cause or a consequence in Hashimoto thyroiditis. Further studies are required.
- 1 September 2015
- Published by Elsevier in Clinical Biochemistry
- Vol. 48 (13-14) , 919-922
Stability of urine specimens stored with and without preservatives at room temperature and on ice prior to urinalysis
- 1 September 2015
- Published by Elsevier in Clinical Biochemistry
- Vol. 48 (13-14) , 919-922
Stability of urine specimens stored with and without preservatives at room temperature and on ice prior to urinalysis
- 1 May 2015
- Published by Bioscientifica in Endocrine Abstracts
Dynamic thiol/disulfide homeostasis in patients with newly diagnosed type 2 diabetes mellitus
Background: Thiol/disulfide homeostasis plays an important role in antioxidative defense mechanism, detoxification, signal transport, management of enzyme activity and trascription factors, and apoptosis. When thiol/disulphide homeostasis breaks down, these important cellular functions get deranged. Pathologies secondary to oxidative stress are seen in organeles in which this homeostasis is deranged. The aim of the study was to investigate dynamic thiol/disulfide homeostasis in newly diagnosed type 2 diabetes mellitus. Materials and methods: Blood thiol/disulfide homeostasis status, that consists of native thiol–disulphide exchanges, was investigated in 60 patients (22 males and 38 females) diagnosed with type 2 diabetes mellitus and 60 healthy control subjects (25 males and 35 females). Serum native thiol and total thiol concentrations were measured as a paired test. The half of the difference between total thiol and native thiol concentrations gave the disulphide bond amount. Results: In comparison to the control group, patients with diabetes mellitus had lower levels of serum thiol and total thiol (340.7±46.1 μmol/l vs 313.7±57.4 μmol/l; P=0.005 and 366.7±46.7 μmol/l vs 343.7±59.0 μmol/l; P=0.020 respectively) while higher average disulfide level (12.9±3.2 μmol/l vs 15.0±4.6 μmol/l; P=0.008). In patients with diabetes mellitus, average disulfide/thiol ratio (%) (3.9±1.2 vs 5.0±1.6; P=0.001) and disulfide/total thiol ratio (%) (3.6±1.0 vs 4.5±1.6; P=0.001) was higher while average thiol/total thiol ratio (%) was lower (92.8±2.1 vs 91.0±3.4; P=0.001) than the control group. HbA1c level and age correlated positively with serum disulfide/thiol ratio and disulfide/total thiol ratio (r=0.239, P=0.009 and r=0.228, P=0.012 respectively) while thiol/total thiol ratio was correlated negatively (r=−0.228, P=0.012). Conclusion: A tendency towards disulfide formation in thiol/disulfide homeostasis was found in patients with diabetes mellitus and there was a positive correlation between HbA1c and disulfide/thiol ratio.
- 1 May 2015
- Published by Bioscientifica in Endocrine Abstracts
Dynamic thiol/disulfide homeostasis in patients with newly diagnosed type 2 diabetes mellitus
Background: Thiol/disulfide homeostasis plays an important role in antioxidative defense mechanism, detoxification, signal transport, management of enzyme activity and trascription factors, and apoptosis. When thiol/disulphide homeostasis breaks down, these important cellular functions get deranged. Pathologies secondary to oxidative stress are seen in organeles in which this homeostasis is deranged. The aim of the study was to investigate dynamic thiol/disulfide homeostasis in newly diagnosed type 2 diabetes mellitus. Materials and methods: Blood thiol/disulfide homeostasis status, that consists of native thiol–disulphide exchanges, was investigated in 60 patients (22 males and 38 females) diagnosed with type 2 diabetes mellitus and 60 healthy control subjects (25 males and 35 females). Serum native thiol and total thiol concentrations were measured as a paired test. The half of the difference between total thiol and native thiol concentrations gave the disulphide bond amount. Results: In comparison to the control group, patients with diabetes mellitus had lower levels of serum thiol and total thiol (340.7±46.1 μmol/l vs 313.7±57.4 μmol/l; P=0.005 and 366.7±46.7 μmol/l vs 343.7±59.0 μmol/l; P=0.020 respectively) while higher average disulfide level (12.9±3.2 μmol/l vs 15.0±4.6 μmol/l; P=0.008). In patients with diabetes mellitus, average disulfide/thiol ratio (%) (3.9±1.2 vs 5.0±1.6; P=0.001) and disulfide/total thiol ratio (%) (3.6±1.0 vs 4.5±1.6; P=0.001) was higher while average thiol/total thiol ratio (%) was lower (92.8±2.1 vs 91.0±3.4; P=0.001) than the control group. HbA1c level and age correlated positively with serum disulfide/thiol ratio and disulfide/total thiol ratio (r=0.239, P=0.009 and r=0.228, P=0.012 respectively) while thiol/total thiol ratio was correlated negatively (r=−0.228, P=0.012). Conclusion: A tendency towards disulfide formation in thiol/disulfide homeostasis was found in patients with diabetes mellitus and there was a positive correlation between HbA1c and disulfide/thiol ratio.
- 27 January 2015
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 31 (3) , 547-556
Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer
Trastuzumab induced cardiotoxicity (TIC) was defined as the most serious side effect. Long term cardiac effects of trastuzumab are still not known, thus we aimed to compare the long term cardiac effects of adjuvant trastuzumab therapies of HER2-positive breast cancer according to the treatment duration.Patients who completed adjuvant trastuzumab treatment at least 6 months before for the adjuvant setting in HER2-positive breast cancer were included in the study. A total of 164 patients were included in this study: 108 and 56 patients were treated with 9 weeks and 52 weeks of trastuzumab, respectively. The main limitation of our study is that due to the cross-sectional evaluation of cardiac biomarkers we cannot predict the status of baseline cardiac biomarkers of this population.The median follow-up of the study was 32 (10-95) months. The accompanying chronic diseases were similar in both groups. Baseline left ventricular ejection fraction (LVEF) was 65.5 ± 3.4% vs 67.1 ± 4.5% in the 9 weeks and 52 weeks trastuzumab treatment groups, respectively (p = 0.13). Symptomatic heart failure was not observed during trastuzumab treatment in either group. Trastuzumab induced cardiotoxicity (TIC) was observed in 2 (1.9%) and 17 (30.3%) patients in the 9 and 52 weeks trastuzumab treatment groups, respectively (p < 0.001). After a median 24 months of follow-up from the last dose of trastuzumab, mean LVEF values were similar between the two treatment arms (p = 0.29). In the subgroup analyses, mean LVEF values were significantly lower in patients who developed TIC compared to those who did not develop TIC (61.9 ± 3.6% vs 64.4 ± 2.6%, p = 0.04). Average mean LVEF loss from baseline was significantly higher in patients who developed TIC compared to those who did not develop TIC (10.0 ± 6.0% vs 1.5 ± 6.2%, p < 0.001). Cardiac biomarkers were similar in both treatment groups. In the subgroup analyses serum High-sensitivity C-reactive protein (hs-CRP) and prohormone brain natriuretic peptide (pro-BNP) levels were significantly higher in patients who developed TIC compared to those who did not develop TIC.TIC was observed to be significantly higher in the 52 weeks trastuzumab group. At the end of 32 months of follow-up mean LVEF values and cardiac biomarkers were similar between the two treatment groups. In the subgroup analyses, significant LVEF loss and higher cardiac biomarkers which show cardiac damage in patients who developed TIC can be permanent in some of the patients and long term cardiac damage may be underestimated.
- 27 January 2015
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 31 (3) , 547-556
Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer
Trastuzumab induced cardiotoxicity (TIC) was defined as the most serious side effect. Long term cardiac effects of trastuzumab are still not known, thus we aimed to compare the long term cardiac effects of adjuvant trastuzumab therapies of HER2-positive breast cancer according to the treatment duration.Patients who completed adjuvant trastuzumab treatment at least 6 months before for the adjuvant setting in HER2-positive breast cancer were included in the study. A total of 164 patients were included in this study: 108 and 56 patients were treated with 9 weeks and 52 weeks of trastuzumab, respectively. The main limitation of our study is that due to the cross-sectional evaluation of cardiac biomarkers we cannot predict the status of baseline cardiac biomarkers of this population.The median follow-up of the study was 32 (10-95) months. The accompanying chronic diseases were similar in both groups. Baseline left ventricular ejection fraction (LVEF) was 65.5 ± 3.4% vs 67.1 ± 4.5% in the 9 weeks and 52 weeks trastuzumab treatment groups, respectively (p = 0.13). Symptomatic heart failure was not observed during trastuzumab treatment in either group. Trastuzumab induced cardiotoxicity (TIC) was observed in 2 (1.9%) and 17 (30.3%) patients in the 9 and 52 weeks trastuzumab treatment groups, respectively (p < 0.001). After a median 24 months of follow-up from the last dose of trastuzumab, mean LVEF values were similar between the two treatment arms (p = 0.29). In the subgroup analyses, mean LVEF values were significantly lower in patients who developed TIC compared to those who did not develop TIC (61.9 ± 3.6% vs 64.4 ± 2.6%, p = 0.04). Average mean LVEF loss from baseline was significantly higher in patients who developed TIC compared to those who did not develop TIC (10.0 ± 6.0% vs 1.5 ± 6.2%, p < 0.001). Cardiac biomarkers were similar in both treatment groups. In the subgroup analyses serum High-sensitivity C-reactive protein (hs-CRP) and prohormone brain natriuretic peptide (pro-BNP) levels were significantly higher in patients who developed TIC compared to those who did not develop TIC.TIC was observed to be significantly higher in the 52 weeks trastuzumab group. At the end of 32 months of follow-up mean LVEF values and cardiac biomarkers were similar between the two treatment groups. In the subgroup analyses, significant LVEF loss and higher cardiac biomarkers which show cardiac damage in patients who developed TIC can be permanent in some of the patients and long term cardiac damage may be underestimated.